Medisys Technologies, Inc. Announces First Orders for CoverTip Safety Syringe
BEDMINSTER, N.J.--(BW HealthWire)--Jan. 10, 2001--Medisys Technologies, Inc. (OTCBB: SCEP) has received its first orders for the company's proprietary hypodermic safety syringe. Four multi-market distributors have placed orders over the last three weeks for the company's CoverTip(TM) syringe, which offers superior point of injection protection, one-handed operation and passive activation.
These initial contracts mark a significant milestone for Medisys as they illustrate acceptance and support from the medical field for the company's patented device. These contracts catapult Medisys into the multi-billion dollar syringe market, providing considerable potential for the company's sales volume. Medisys expects these orders to be the first of many and will continue to supply trial syringes to select hospitals throughout the United States.
"I am ecstatic to see our safety syringes being used in the field," reported Kerry Frey, President and COO of Medisys Technologies. "Medisys is confident that our innovative safety syringe will provide superior and more affordable protection to doctors and nurses that fall victim to the risk of accidental needlesticks."
About Medisys Technologies
Medisys Technologies, Inc. is a diversified medical company that develops, manufactures and markets patented products for improving safety and patient care. Spurred by recent Federal Regulations and State Safety Legislation Medisys is currently concentrating on commercializing its portfolio of patented needle safety technology, with unique features and competitive advantages over other safety devices.
In addition to the CoverTip hypodermic syringe, the Medisys portfolio of patented safety devices includes: BXDraw(TM), a fine needle biopsy/aspiration safety syringe; SofDraw(TM), a blood and fluid collection safety syringe; and MultiDraw(TM), a needleless multiple vacuum vial blood collection safety device. The Company has a total of 19 patent applications for new safety designs in blood collection, capillary blood testing, and tissue excision cutting needles and has granted 510K clearance by the FDA to market its products.
For more information about Medisys Technology and its proprietary suite of needle safety technologies, please contact Shayne Payne, Juan Dominguez or Dian Griesel, Ph.D. at the Investor Relations Group: 212 736 2650 or visit us on the web at www.medisystech.com
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting the Company's operations, markets, products and prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.
CONTACT:
Investor Relations Group
Shayne Payne, Juan Dominguez or Dian Griesel, Ph.D.
212/736-2650
KEYWORD: NEW JERSEY
BW2526 JAN 10,2001
11:32 PACIFIC
14:32 EASTERN
